文献速递衰弱、肌少症与跌倒老年慢病共病管理

降压药减量对老年患者短期血压控制的影响:OPTiMISE试验结果校准至真实世界初级保健数据

Effect of antihypertensive medication reduction on short-term blood pressure control in older adults: calibration of OPTiMISE trial results to real-world primary care data.
PubMed 文献 · Age Ageing · 2026-01-01

本研究将OPTiMISE试验中减停一种降压药的效果校准至英格兰真实世界初级保健人群。经逆概率加权校准后,减停降压药与住院或死亡风险升高无关(校准HR 0.94,95%CI 0.73-1.22),提示试验结果可外推至真实世界人群。

要点

  • OPTiMISE试验中减停一种降压药未导致短期血压控制恶化,长期随访未观察到危害。
  • 校准后目标人群中明显衰弱者比例高于试验参与者(25% vs 11%)。
  • 校准后减停降压药与住院或死亡风险升高无关(HR 0.94,95%CI 0.73-1.22)。

核心结论

  • 将OPTiMISE试验结果校准至比原试验参与者更衰弱的代表性初级保健人群后,减停一种降压药与住院或死亡风险升高无关,提示原试验结果可转化至真实世界人群。

研究设计与样本

  • 基于OPTiMISE试验(纳入569名≥80岁、血压控制且使用≥2种降压药的成人)的治疗效应,采用逆概率加权(IPW)按试验纳入可能性进行校准。
  • 目标人群由24家参与实践的电子健康记录重建,并外推至全英格兰≥80岁、使用≥2种降压药的成人(基于NHS Digital数据)。
  • 主要结局为全因住院或死亡,采用加权Cox模型估计校准风险比(HR)。

主要发现

  • 目标人群中明显衰弱者比例为25%,高于OPTiMISE参与者的11%。
  • 经IPW校准后,减停降压药与住院或死亡风险升高无关(校准HR 0.94,95%CI 0.73-1.22),与OPTiMISE长期随访结果(HR 0.93,95%CI 0.76-1.12)相似,但置信区间略宽。

临床怎么用

  • 在≥80岁、血压控制且使用≥2种降压药的老年患者中,可考虑减停一种降压药而不必担心短期住院或死亡风险升高。
  • 对于衰弱老年患者,减停降压药的决策可参考OPTiMISE校准后的结果,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While antihypertensive treatment prevents cardiovascular events, it may also increase risks such as falls in patients with frailty. The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTiMISE) trial found that deprescribing one antihypertensive drug did not result in worse short-term blood pressure control and long-term follow-up showed no observed harm, but its generalisability to routine clinical practice remains uncertain. OBJECTIVE: This study aimed to calibrate the OPTiMISE effect to a representative primary care population in England. METHODS: We calibrated the OPTiMISE treatment effect using inverse probability weighting (IPW) based on trial inclusion likelihood. The trial enrolled 569 adults aged ≥80 years with controlled blood pressure on ≥2 antihypertensive drugs. A target population was reconstructed from electronic health records of 24 participating practices and extrapolated to all English adults aged ≥80 years, prescribed ≥2 antihypertensive drugs, using NHS Digital data. The primary outcome was all-cause hospitalisation or death. Weighted Cox models estimated calibrated hazard ratios (HRs). RESULTS: The target population included 798 179 individuals (median age 84 years [81-87], 48% female). Compared with OPTiMISE participants, a higher proportion of individuals in target population were overtly frail (25% vs. 11%). After calibration using IPW, deprescribing was not associated with higher risk of hospitalisation or death [calibrated HR 0.94 (95% CI: 0.73-1.22)], similar to the long-term follow-up of OPTiMISE [HR 0.93 (95% CI: 0.76-1.12)], although with a slightly wider confidence interval. CONCLUSIONS: Calibrating OPTiMISE findings to a representative primary care population frailer than the original participants suggests that the original trial findings could be translated into a real-world population.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Christiaens A, Wang A, McAllister DA, et al. Effect of antihypertensive medication reduction on short-term blood pressure control in older adults: calibration of OPTiMISE trial results to real-world primary care data. Age Ageing. 2026. PMID: 42381392. doi:10.1093/ageing/afag192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。